According to multi-industry laboratory company Intertek, it has acquired OINDP testing specialist Melbourn Scientific. In its announcement, Intertek cites Melbourn’s “profound expertise in all aspects of characterization of orally inhaled and intra-nasal products (OINDP)” and “an increasing demand worldwide for more patient friendly drug delivery methods for optimum therapeutic efficacy and efficiency and enhanced patient outcomes.”
Intertek Chemicals and Pharmaceuticals Senior VP Andrew Swift commented, “Combining Intertek’s GMP/ GLP pharmaceutical/ biopharmaceutical studies and our advanced capabilities for measuring device/ drug interaction with Melbourn’s expertise in OINDP drug characterization provides a unique and compelling offering to clients. Adding in our global reach and Regulatory Services, Intertek now offers a comprehensive and global end to end expert service to support drug development which is unmatched by current competitors.”
Read the Intertek press release.
